Highlights OBI Pharma, Inc.

Equities

4174

TW0004174008

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-07-15 pm EDT			5-day change	1st Jan Change
63.3 ^TWD	+0.32%		-3.36%	-8.79%

Jun. 17	Obi Pharma, Inc. Announces Obi-992 Trop2 ADC Has Been Granted by TFDA to Proceed to Phase I/Ii Human Clinical Trial	CI
May. 30	OBI Pharma, Inc. Files the Application of Phase I/II human clinical trial for OBI-992 TROP2 ADC to TFDA	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Obi Pharma, Inc. Announces Obi-992 Trop2 ADC Has Been Granted by TFDA to Proceed to Phase I/Ii Human Clinical Trial	Jun. 17	CI
OBI Pharma, Inc. Files the Application of Phase I/II human clinical trial for OBI-992 TROP2 ADC to TFDA	May. 30	CI
OBI Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
Obi Pharma, Inc. Announces the Termination of License Agreement with Odeon for the Rights of Obi-999 and Obi-833 in China, Hong Kong and Macau	May. 10	CI
OBI Pharma, Inc. Announces OBIGEN TFDA Clearance of IND Application for A Phase II Human Clinical Trial	May. 02	CI
OBI Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 25	CI
Obi Pharma, Inc. Announces the Termination of Obi-3424-001 Trial While Continuing the Collaboration Of obi-3424 with Partners	Mar. 11	CI
OBI Pharma, Inc. Announces Adagloxad Simolenin (OBI-822) Receives Positive 1st Interim Analysis Recommendation, Recommending the Continues of the Phase III TNBC Trial	Jan. 31	CI
OBI Pharma, Inc. Announces OBI-992 TROP2 ADC Has Been Granted by US FDA to Proceed to Phase I/II Human Clinical Trial	Jan. 03	CI
Obi Pharma, Inc. Files the Application of Phase I/II Human Clinical Trial for OBI-992 TROP2 ADC to US FDA	Dec. 01	CI
OBI Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
OBI Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
OBI Pharma, Inc. Announces COVID-19 Vaccine, BCVax, Has Been Granted by TFDA to Proceed to Phase I Clinical Trial	23-06-02	CI
OBI Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
OBI Pharma, Inc. Files the Application of Phase I Human Clinical Trial for COVID-19 Vaccine, BCVax, to TfDA	23-03-31	CI
OBI Pharma, Inc.(TPEX:4174) dropped from FTSE All-World Index	23-03-20	CI
OBI Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-15	CI
OBI Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-15	CI
Obi Pharma, Inc. Files Application for Phase II Human Clinical Trial of First-In-Class Novel Prodrug, Obi-3424, to TFDA	23-02-02	CI
United States Patent and Trademark Office Grants Patent for OBI-866 Immunogenic/Therapeutic Glycan Compositions and Uses Thereof	22-12-23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights OBI Pharma, Inc.

Equities

4174

TW0004174008

Highlights

Filters